Kindstar has also agreed to purchase Genesis systems for use by its scientists to monitor circulating tumor cells and for single-cell research.
The guidance calls for communication to ensure doctors and patients understand what tests might be affected and to keep labs informed about patients' biotin intake.
GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The decision means the ruling by an appeals court that Mayo did not infringe on Athena's patent on a method of diagnosing myasthenia gravis will stand.
Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.
The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.
Contextual Genomics' recently launched assay screens for cell-free circulating tumor DNA in plasma to identify somatic genome alterations.
The alliance will leverage Charleston, Veravas' sample prep technology and Tymora's extracellular vesicle enrichment technology.